Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.

Blood
Megan D HobanDonald B Kohn

Abstract

Sickle cell disease (SCD) is characterized by a single point mutation in the seventh codon of the β-globin gene. Site-specific correction of the sickle mutation in hematopoietic stem cells would allow for permanent production of normal red blood cells. Using zinc-finger nucleases (ZFNs) designed to flank the sickle mutation, we demonstrate efficient targeted cleavage at the β-globin locus with minimal off-target modification. By co-delivering a homologous donor template (either an integrase-defective lentiviral vector or a DNA oligonucleotide), high levels of gene modification were achieved in CD34(+) hematopoietic stem and progenitor cells. Modified cells maintained their ability to engraft NOD/SCID/IL2rγ(null) mice and to produce cells from multiple lineages, although with a reduction in the modification levels relative to the in vitro samples. Importantly, ZFN-driven gene correction in CD34(+) cells from the bone marrow of patients with SCD resulted in the production of wild-type hemoglobin tetramers.

References

Jan 15, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M C WaltersUNKNOWN Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease
Nov 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Francesca StoriciMichael A Resnick
Dec 28, 2004·Nature Biotechnology·Marie-Catherine GiarratanaLuc Douay
Mar 25, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sarah J NightingaleDonald B Kohn
Jul 14, 2010·Cell Stem Cell·Mary MohrinEmmanuelle Passegué
Sep 17, 2010·Nature·Marina Cavazzana-CalvoPhilippe Leboulch
Jul 19, 2011·Nature Methods·Fuqiang ChenGregory D Davis
Aug 9, 2011·Nature Biotechnology·Richard GabrielChristof von Kalle
Sep 3, 2011·Blood·Marie-Catherine GiarratanaLuc Douay
Jan 22, 2013·Human Gene Therapy·Alessia CavazzaFulvio Mavilio
Jul 3, 2013·Cold Spring Harbor Perspectives in Medicine·Graham R Serjeant
Jul 17, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alok V JoglekarDonald B Kohn
Jul 19, 2013·The Journal of Clinical Investigation·Zulema RomeroDonald B Kohn
Oct 26, 2013·Nucleic Acids Research·Richard A VoitMatthew H Porteus
Mar 5, 2014·Hematology/oncology Clinics of North America·Shanmuganathan Chandrakasan, Punam Malik
Mar 7, 2014·The New England Journal of Medicine·Pablo TebasCarl H June
May 30, 2014·Nature·Pietro GenoveseLuigi Naldini

❮ Previous
Next ❯

Citations

Jan 13, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Morgan L Maeder, Charles A Gersbach
Jan 15, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Versha PrakashRafael J Yáñez-Muñoz
Dec 24, 2015·Genome Biology·Matthew H Porteus
Oct 28, 2015·Journal of Molecular Biology·Srinivasan Chandrasegaran, Dana Carroll
Dec 10, 2015·Nature Biotechnology·Giorgia Santilli, Adrian J Thrasher
Sep 8, 2015·Current Opinion in Pharmacology·Claudio MussolinoToni Cathomen
Sep 5, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiaoyu Chen, Manuel A F V Gonçalves
Dec 15, 2015·Molecular Therapy. Methods & Clinical Development·Tamara I PestinaDerek A Persons
Oct 16, 2015·Nature·Luigi Naldini
Sep 4, 2015·Journal of Molecular Biology·Viktor Haellman, Martin Fussenegger
Jul 17, 2015·American Journal of Hematology·Natasha ArcherCarlo Brugnara
Mar 30, 2016·Human Gene Therapy·Jorge Mansilla-SotoMichel Sadelain
Apr 8, 2016·Current Opinion in Hematology·Gregory J Kato
Apr 25, 2015·Blood·Jakub Tolar
May 6, 2016·Plant Cell Reports·Helga Schinkel, Stefan Schillberg
Apr 8, 2016·Blood·Matthew C Canver, Stuart H Orkin
Apr 8, 2016·Blood·Megan D Hoban, Daniel E Bauer
Jun 3, 2016·Human Genetics·Ipek TasanHuimin Zhao
Jun 9, 2016·Advanced Drug Delivery Reviews·Kelly A Schwarz, Joshua N Leonard
May 6, 2016·Annual Review of Chemical and Biomolecular Engineering·Christopher E Nelson, Charles A Gersbach
Jun 28, 2016·Experimental Hematology·Ah Ram Kim, Vijay G Sankaran
Jun 15, 2016·American Journal of Hematology·Philipp M AltrockFranziska Michor
Jul 14, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Megan D HobanDonald B Kohn
Sep 7, 2016·The Journal of Clinical Investigation·Christian BrendelDavid A Williams
Oct 19, 2016·Stem Cells and Development·Drake J SmithLili Yang
Sep 8, 2016·Proceedings of the National Academy of Sciences of the United States of America·Lin YeYuet Wai Kan
Oct 14, 2016·Blood Cells, Molecules & Diseases·Xiaotang Hu
Oct 30, 2016·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Leif S LudwigVijay G Sankaran
Nov 8, 2016·Nature·Daniel P DeverMatthew H Porteus
Dec 23, 2016·Nature Reviews. Drug Discovery·Christof FellmannJacob E Corn
Jan 11, 2017·Hämostaseologie·Simone A HaasToni Cathomen
Apr 8, 2017·Nature Medicine·Tatjana I CornuToni Cathomen
Apr 11, 2017·Acta Pharmacologica Sinica·Gayong ShimYu-Kyoung Oh
Apr 6, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marina CavazzanaAnnarita Miccio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.